279 related articles for article (PubMed ID: 32486027)
21. Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor.
Stabile H; Mitola S; Moroni E; Belleri M; Nicoli S; Coltrini D; Peri F; Pessi A; Orsatti L; Talamo F; Castronovo V; Waltregny D; Cotelli F; Ribatti D; Presta M
Blood; 2007 Mar; 109(5):1834-40. PubMed ID: 17077323
[TBL] [Abstract][Full Text] [Related]
22. In Xenopus embryos, BMP heterodimers are not required for mesoderm induction, but BMP activity is necessary for dorsal/ventral patterning.
Eimon PM; Harland RM
Dev Biol; 1999 Dec; 216(1):29-40. PubMed ID: 10588861
[TBL] [Abstract][Full Text] [Related]
23. Paresis of a bone morphogenetic protein-antagonist response in a genetic disorder of heterotopic skeletogenesis.
Ahn J; Serrano de la Pena L; Shore EM; Kaplan FS
J Bone Joint Surg Am; 2003 Apr; 85(4):667-74. PubMed ID: 12672843
[TBL] [Abstract][Full Text] [Related]
24. Bi-directional roles of bone morphogenetic proteins in cancer: another molecular Jekyll and Hyde?
Ehata S; Yokoyama Y; Takahashi K; Miyazono K
Pathol Int; 2013 Jun; 63(6):287-96. PubMed ID: 23782330
[TBL] [Abstract][Full Text] [Related]
25. Bone morphogenetic protein (BMP) signaling regulates mitotic checkpoint protein levels in human breast cancer cells.
Yan H; Zhu S; Song C; Liu N; Kang J
Cell Signal; 2012 Apr; 24(4):961-8. PubMed ID: 22234345
[TBL] [Abstract][Full Text] [Related]
26. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
27. Differentiation of murine preosteoblastic KS483 cells depends on autocrine bone morphogenetic protein signaling during all phases of osteoblast formation.
van der Horst G; van Bezooijen RL; Deckers MM; Hoogendam J; Visser A; Löwik CW; Karperien M
Bone; 2002 Dec; 31(6):661-9. PubMed ID: 12531559
[TBL] [Abstract][Full Text] [Related]
28. Effects of TGF-beta2, BMP-4, and gremlin in the trabecular meshwork: implications for glaucoma.
Wordinger RJ; Fleenor DL; Hellberg PE; Pang IH; Tovar TO; Zode GS; Fuller JA; Clark AF
Invest Ophthalmol Vis Sci; 2007 Mar; 48(3):1191-200. PubMed ID: 17325163
[TBL] [Abstract][Full Text] [Related]
29. Noggin regulation of bone morphogenetic protein (BMP) 2/7 heterodimer activity in vitro.
Zhu W; Kim J; Cheng C; Rawlins BA; Boachie-Adjei O; Crystal RG; Hidaka C
Bone; 2006 Jul; 39(1):61-71. PubMed ID: 16488673
[TBL] [Abstract][Full Text] [Related]
30. Extracellular BMP-antagonist regulation in development and disease: tied up in knots.
Walsh DW; Godson C; Brazil DP; Martin F
Trends Cell Biol; 2010 May; 20(5):244-56. PubMed ID: 20188563
[TBL] [Abstract][Full Text] [Related]
31. Endogenous bone morphogenetic protein antagonists regulate mammalian neural crest generation and survival.
Anderson RM; Stottmann RW; Choi M; Klingensmith J
Dev Dyn; 2006 Sep; 235(9):2507-20. PubMed ID: 16894609
[TBL] [Abstract][Full Text] [Related]
32. Co-expression of BMPs and BMP-inhibitors in human fractures and non-unions.
Kloen P; Lauzier D; Hamdy RC
Bone; 2012 Jul; 51(1):59-68. PubMed ID: 22521262
[TBL] [Abstract][Full Text] [Related]
33. Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists.
Ye L; Lewis-Russell JM; Kynaston H; Jiang WG
J Urol; 2007 Sep; 178(3 Pt 1):1086-91. PubMed ID: 17644136
[TBL] [Abstract][Full Text] [Related]
34. TGF-β, Bone Morphogenetic Protein, and Activin Signaling and the Tumor Microenvironment.
Pickup MW; Owens P; Moses HL
Cold Spring Harb Perspect Biol; 2017 May; 9(5):. PubMed ID: 28062564
[TBL] [Abstract][Full Text] [Related]
35. Controlling BMP growth factor bioavailability: The extracellular matrix as multi skilled platform.
Zimmermann LA; Correns A; Furlan AG; Spanou CES; Sengle G
Cell Signal; 2021 Sep; 85():110071. PubMed ID: 34217834
[TBL] [Abstract][Full Text] [Related]
36. DRAGON, a bone morphogenetic protein co-receptor.
Samad TA; Rebbapragada A; Bell E; Zhang Y; Sidis Y; Jeong SJ; Campagna JA; Perusini S; Fabrizio DA; Schneyer AL; Lin HY; Brivanlou AH; Attisano L; Woolf CJ
J Biol Chem; 2005 Apr; 280(14):14122-9. PubMed ID: 15671031
[TBL] [Abstract][Full Text] [Related]
37. Structure analysis of bone morphogenetic protein-2 type I receptor complexes reveals a mechanism of receptor inactivation in juvenile polyposis syndrome.
Kotzsch A; Nickel J; Seher A; Heinecke K; van Geersdaele L; Herrmann T; Sebald W; Mueller TD
J Biol Chem; 2008 Feb; 283(9):5876-87. PubMed ID: 18160401
[TBL] [Abstract][Full Text] [Related]
38. BMP signalling: agony and antagony in the family.
Brazil DP; Church RH; Surae S; Godson C; Martin F
Trends Cell Biol; 2015 May; 25(5):249-64. PubMed ID: 25592806
[TBL] [Abstract][Full Text] [Related]
39. Interplay between bone morphogenetic proteins and cognate binding proteins in bone and cartilage development: noggin, chordin and DAN.
Reddi AH
Arthritis Res; 2001; 3(1):1-5. PubMed ID: 11178121
[TBL] [Abstract][Full Text] [Related]
40. Structure of Gremlin-1 and analysis of its interaction with BMP-2.
Kišonaitė M; Wang X; Hyvönen M
Biochem J; 2016 Jun; 473(11):1593-604. PubMed ID: 27036124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
